Hemo Organic
- Market cap
- ₹ 8 Cr.
- P/E
- 74.1x
- P/B
- 59.9x
- ROCE
- −23.8%
- Dividend yield
- 0%
- Debt / equity
- 20.62
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE
About
Hemo Organic Limited is an India-based company engaged in the manufacturing of ayurvedik or unani pharmaceutical preparations. The Company is presently engaged in the business of manufacturing, trading, and dealing with chemicals, dyes, pigments, auxiliaries, intermediates, heavy and fine chemicals, organic and inorganic chemicals, among others. It is also engaged in formulation, processing, and development of pharmaceutical products, nutraceuticals, and healthcare supplements.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Hemo Organic against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)74.1 against a typical 28.5: pricier than most peers (1st = cheapest).133rd of 186
- Size₹ 8 Cr. market value against a typical ₹ 26.8 Cr. (1st = largest).148th of 183
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Expenses | −0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 |
| Operating Profit | 0 | 0 | −0 | 0 | −0 | −0 | 0 | −0 | −0 | −0 | −0 | −0 |
| OPM % | — | — | −1,050% | — | — | — | 6.2% | — | — | — | −32.3% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | −0 | 0 | −0 | −0 | 0 | −0 | −0 | −0 | −0 | −0 |
| Tax % | 0% | — | 0% | — | 0% | 0% | −58.3% | −27.3% | −25% | 220% | 70% | 0% |
| Net Profit | 0 | 0 | −0 | 0 | −0 | −0 | 0 | −0 | −0 | −0 | −1 | −0 |
| EPS in Rs | 0.03 | 0 | −0.66 | 0 | −0.23 | −0.23 | 1.07 | −0.26 | −0.09 | −0.46 | −1.47 | −0.2 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 24%
- 5 Years
- 148%
- 3 Years
- —
- TTM
- −61%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −742%
- 10 Years
- 4%
- 5 Years
- 16%
- 3 Years
- 48%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Hemo Organic | — | ₹ 8 Cr. | 74.1x | 59.9x | — | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 39.4x | 5.7x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 95.8x | 15x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 77.4x | 20.4x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.5x | 4.3x | — | 15.7% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.4x | 3.3x | — | 11.9% |
Management
- Murlidhar Joshi
- Chief Financial Officer, Non-Executive Director
- Yukta Prakash Patel
- Company Secretary and Compliance Officer
- Vishwambar Kameshwar Singh
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.